Immunocore Holdings Stock Revenue
| IMCR Stock | USD 32.12 0.30 0.93% |
Immunocore Holdings fundamentals help investors to digest information that contributes to Immunocore Holdings' financial success or failures. It also enables traders to predict the movement of Immunocore Stock. The fundamental analysis module provides a way to measure Immunocore Holdings' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunocore Holdings stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 249.4 M | 261.9 M |
Immunocore | Revenue |
Immunocore Holdings Company Revenue Analysis
Immunocore Holdings' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Immunocore Holdings Revenue | 249.43 M |
Most of Immunocore Holdings' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunocore Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Immunocore
Projected quarterly revenue analysis of Immunocore Holdings provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Immunocore Holdings match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Immunocore Holdings' stock price.
Immunocore Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Immunocore Holdings is extremely important. It helps to project a fair market value of Immunocore Stock properly, considering its historical fundamentals such as Revenue. Since Immunocore Holdings' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immunocore Holdings' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immunocore Holdings' interrelated accounts and indicators.
| -0.89 | 0.99 | 0.97 | -0.88 | -0.88 | ||
| -0.89 | -0.94 | -0.81 | 1.0 | 0.92 | ||
| 0.99 | -0.94 | 0.93 | -0.93 | -0.94 | ||
| 0.97 | -0.81 | 0.93 | -0.79 | -0.77 | ||
| -0.88 | 1.0 | -0.93 | -0.79 | 0.93 | ||
| -0.88 | 0.92 | -0.94 | -0.77 | 0.93 |
Click cells to compare fundamentals
Immunocore Revenue Historical Pattern
Today, most investors in Immunocore Holdings Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Immunocore Holdings' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Immunocore Holdings revenue as a starting point in their analysis.
Immunocore Holdings Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Immunocore Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Immunocore Holdings reported 249.43 M of revenue. This is 96.73% lower than that of the Biotechnology sector and 66.43% lower than that of the Health Care industry. The revenue for all United States stocks is 97.36% higher than that of the company.
Immunocore Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunocore Holdings' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunocore Holdings could also be used in its relative valuation, which is a method of valuing Immunocore Holdings by comparing valuation metrics of similar companies.Immunocore Holdings is currently under evaluation in revenue category among its peers.
Immunocore Holdings Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immunocore Holdings from analyzing Immunocore Holdings' financial statements. These drivers represent accounts that assess Immunocore Holdings' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immunocore Holdings' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 889.5M | 1.0B | 1.1B | 2.2B | 3.3B | 3.5B | |
| Enterprise Value | 875.0M | 939.1M | 900.8M | 1.9B | 3.0B | 3.1B |
Immunocore Holdings ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Immunocore Holdings' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Immunocore Holdings' managers, analysts, and investors.Environmental | Governance | Social |
Immunocore Holdings Institutional Holders
Institutional Holdings refers to the ownership stake in Immunocore Holdings that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Immunocore Holdings' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Immunocore Holdings' value.| Shares | Fiera Capital Corporation | 2024-06-30 | 875.6 K | Blackrock Inc | 2024-06-30 | 871.8 K | Millennium Management Llc | 2024-06-30 | 601 K | Bill & Melinda Gates Foundation | 2024-06-30 | 576.9 K | Principal Financial Group Inc | 2024-09-30 | 546.3 K | Polar Capital Holdings Plc | 2024-06-30 | 502.6 K | Massachusetts Financial Services Company | 2024-09-30 | 498.2 K | Two Sigma Advisers, Llc | 2024-06-30 | 457.5 K | Two Sigma Investments Llc | 2024-06-30 | 439.5 K | T. Rowe Price Investment Management,inc. | 2024-09-30 | 6.5 M | Wellington Management Company Llp | 2024-06-30 | 6.4 M |
Immunocore Fundamentals
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0522 | ||||
| Profit Margin | (0.16) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 1.2 B | ||||
| Shares Outstanding | 50.03 M | ||||
| Shares Owned By Insiders | 5.23 % | ||||
| Shares Owned By Institutions | 94.54 % | ||||
| Number Of Shares Shorted | 7.97 M | ||||
| Price To Book | 4.29 X | ||||
| Price To Sales | 5.47 X | ||||
| Revenue | 249.43 M | ||||
| Gross Profit | 54.11 M | ||||
| EBITDA | (59.65 M) | ||||
| Net Income | (55.29 M) | ||||
| Cash And Equivalents | 208.06 M | ||||
| Cash Per Share | 4.74 X | ||||
| Total Debt | 84.03 M | ||||
| Debt To Equity | 0.41 % | ||||
| Current Ratio | 3.98 X | ||||
| Book Value Per Share | 7.55 X | ||||
| Cash Flow From Operations | 2.94 M | ||||
| Short Ratio | 32.19 X | ||||
| Earnings Per Share | (0.95) X | ||||
| Target Price | 52.51 | ||||
| Number Of Employees | 497 | ||||
| Beta | 0.72 | ||||
| Market Capitalization | 1.62 B | ||||
| Total Asset | 597 M | ||||
| Retained Earnings | (744.67 M) | ||||
| Working Capital | 389.8 M | ||||
| Net Asset | 597 M |
About Immunocore Holdings Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunocore Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunocore Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunocore Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Immunocore Holdings
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunocore Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunocore Holdings will appreciate offsetting losses from the drop in the long position's value.Moving together with Immunocore Stock
Moving against Immunocore Stock
| 0.61 | VRDN | Viridian Therapeutics | PairCorr |
| 0.47 | NTRB | Nutriband | PairCorr |
| 0.45 | BMEA | Biomea Fusion | PairCorr |
| 0.42 | EWTX | Edgewise Therapeutics | PairCorr |
The ability to find closely correlated positions to Immunocore Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunocore Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunocore Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunocore Holdings to buy it.
The correlation of Immunocore Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunocore Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunocore Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immunocore Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Immunocore Stock Analysis
When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.